METHOD FOR FIGHTING AGAINST NON-PERSISTENT VIRUS PROPAGATION, COMPOSITION AND USE

Details for Australian Patent Application No. 2003269061 (hide)

Owner NOVANCE

Inventors VIELLIARD, Antoine; RAVIER, Pierre

Pub. Number AU-A-2003269061

PCT Number PCT/FR03/02360

PCT Pub. Number WO2004/010782

Priority 02/09548 26.07.02 FR

Filing date 25 July 2003

Wipo publication date 16 February 2004

International Classifications

A01N 037/02 Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids - Saturated carboxylic acids or thio-analogues thereof

Event Publications

15 January 2004 Complete Application Filed

  Priority application(s): 02/09548 26.07.02 FR

25 March 2004 Application Open to Public Inspection

  Published as AU-A-2003269061

16 June 2005 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(f)/See Reg. 8.3(3). Examination has not yet been requested or directed for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2003269062-ADHESIVE COMPOSITION FOR MOIST MATERIAL

2003269060-SPECIFIC ISOTYPE ANTIBODIES OF SECRETION-EXCRETION ANTIANTIGENS OF LESS THANIGREATER THANLEISHMANIA SPLESS THAN/IGREATER THAN OF PROMASTIGOTELESS THANIGREATER THAN LESS THAN/ IGREATER THANOR AMASTIGOTE FORMS USED AS PROTECTION, RESISTANCE AND CURING MARKERS OF MAMMALS TO LEISHMANIASES AND TO INTRACELLULAR PATHOGENIC MICRO-ORGANISM INFECTIONS, AND AS IMMUNOTHERAPEUTIC EFFECTORS